GSK banks on promising data from its PhIII Gemini program to stare down Gilead on HIV — but there are plenty of skeptics
After more than a decade’s worth of work, GlaxoSmithKline $GSK researchers today are unveiling pooled data from their two late-stage trials of a two-drug regimen for keeping HIV in check. Facing off against some deep-seated skepticism and a powerhouse rival at Gilead $GILD, the pharma giant’s majority owned subsidiary ViiV says the combo performed just as well as a triplet in their big faceoff involving treatment-naive patients, making it a likely new entry in the global fight against the virus that spurs AIDS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.